New $300 million fund launched to address public health challenges
Backed by Merck, Novartis and the Bill and Melinda Gates Foundation, Adjuvant Capital launched a $300 million oversubscribed fund focused on accelerating the development of medical innovations for historically overlooked public health challenges.
The debut fund will support promising new technologies for indications that the venture capital industry has largely ignored such as malaria, shigella, hookworm, tuberculosis and Lassa fever.
For more information, click here.
